ATX
AMPLIA FPO [ATX]
Healthcare · ASX Small Cap
$0.1350 +0.0%
Updated 3 Sep 2026 · Signals refresh every scan
Appeared in 2 consecutive scansFirst seen: 2026-03-09
Get alerts when ATX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- MACD momentum is losing steam
- Stochastic is deep in oversold territory — bounce conditions forming
- Sitting near support — this level has held before and could attract buyers again
- Drifting lower — down 6.9% over the last 5 days
- Volatility is contracting — like a spring being compressed, breakouts often follow
- Strong cash runway (13 quarters)
- Moderate P/S ratio (14.5x)
- EPS estimates revised upward (+10pts)
- Small-cap ($20-100M)
- CANSLIM I: Institutional ownership (23%)
- Sentiment is mixed — no strong consensus either way
- The bigger volume days are the up days — volume-weighted momentum is positive (3.94%/day)
- RBA hiking (-3pts)
Risk Signals
- Below the 200-day average — the long-term trend is still working against it
- Revenue declining (-9%)
- Piotroski F-Score weak (3/9, low-confidence approx)
- Deeply negative margins (-161%)
- Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about ATX
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Results of Annual General Meeting
NONE CEO Managing Director Presentation to Annual General Meeting
NONE Bioshares Biotech Summit Presentation
MEDIUM Amplia signs Collaboration and Supply Agreement with Lilly
Recent ASX Announcements
| 2026-08-28 | Results of Annual General Meeting |
| 2026-08-27 | CEO Managing Director Presentation to Annual General Meeting |
| 2026-08-06 | Bioshares Biotech Summit Presentation |
| 2026-08-03 | Amplia signs Collaboration and Supply Agreement with Lilly PRICE SENSITIVE |
| 2026-07-30 | Scientific Paper Studies of narmafotinib - Pancreatic Cancer |
Key Metrics
$69.3M
Market Cap
779K
Avg Volume
1.3x
Vol Ratio
$0.10 — $0.28
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
-25.5%
ROE
-160.9%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 81% |
| L | Leader vs Laggard | pass | RS: 11 |
| I | Institutional Sponsorship | pass | Inst: 23% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
113 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track ATX and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required